R D Pullan, S Ganesh, V Mani, J Morris, B K Evans, G T Williams, J Rhodes Abstract An enema that contained a complex ofbismuth citrate and polyacrylate was compared with 5-aminosalicylic acid (5-ASA) enemas for treatment of distal ulcerative colitis. The multicentre trial involving 63 patients was randomised and double blind with enemas given over four weeks; clinical, sigmoidoscopic, and histological assessments were made. Improvements were seen in both treatment groups. Clinical remission was seen in 18 of 32 patients treated with 5-ASA and 12 of 31 patients treated with bismuth citratecarbomer (X2 1-94; p=0-16) . Sigmoidoscopic remission occurred in 20 of 32 patients in the 5-ASA group and 15 of 31 patients given bismuth (X2 1*27; p=026). Improvement of rectal biopsy histology by at least one grade was seen in 16 of 32 patients in the 5-ASA group and 14 of 31 patients with bismuth (X2 015; p=070). Analysis of covariance gave no significant difference between groups, although there was a trend favouring 5-ASA. There was no evidence of bismuth accumulation during the trial. Bismuth enemas may offer a new therapeutic option in distal ulcerative colitis.
In recent years enemas of 5-aminosalicylic acid (5-ASA) have proved effective for treatment of distal ulcerative colitis'2 and results have been comparable with those from steroid enemas.34 In the course of trying to identify therapeutic agents for this disease two recent studies have shown benefit with bismuth preparations.56 Encouraged by these findings we have formulated a bismuth enema and compared it with 5-ASA enemas in patients with active distal colitis to examine the therapeutic effect.
Methods
Sixty eight patients with active left sided ulcerative colitis were identified from gastroenterology outpatients in three centres and randomly allocated to receive either 5-ASA enemas ( (Table I ).9 At the end ofthe study patients were asked whether they found the enemas acceptable or whether they had encountered difficulty in their administration.
The severity of inflammatory change was graded visually at sigmoidoscopy with a scale devised by Baron et al (Table I ).'°A biopsy was taken 8 cm from the anal margin on the anterior rectal wall; these were subsequently examined histologically to assess inflammatory activity, which was graded in a standard manner (Table I) to examine changes over the trial period within each group. As the two treatment groups were not identical in severity of disease at the start of the trial, an analysis of covariance, with corresponding confidence intervals, was used to compare each measure between the groups after treatment, making adjustments for the differences in severity of disease before treatment as measured by the corresponding baseline measurement. The X' test was also used for proportions exhibiting specified changes.
Results
Although 68 patients were admitted to the trial five were subsequently withdrawn from further analysis. Three of these had discontinued treatment themselves after only a few days and failed to keep further appointments, one was found to have severe total colonic disease on colonoscopy, and one was found to have Crohn's disease; none of these five patients had side effects from treatment and were deemed unsuitable for analysis. Of the three who discontinued their own treatment one had multiinfarct dementia and the other two, contacted by phone, had improved but did not wish to take further part in the study. Ofthe remaining 63 patients six were withdrawn before the end of the trial period for reasons given in Table II On admission to the trial those given 5-ASA had less severe symptoms than the bismuth group although the differences in symptoms and in both sigmoidoscopic and histological grades did not achieve statistical significance (Table IV) . The initial global clinical scores for symptoms were 1-7 (SD 0-5) and 1 9 (SD 0 4) respectively for the 5-ASA and bismuth groups. These differences were also reflected in the St Mark's score and grades for sigmoidoscopy and histology in the two groups (Table IV) .
There was a significant improvement in all symptoms with both 5-ASA and bismuth enemas. The improvement was noted in the global clinical assessment, stool frequency, occurrence of blood, changes in stool consistency, occurrence of abdominal pain, urgency, and the patients overall assessment of general well being. The St Mark's score, change in sigmoidoscopic grading, and histology all showed significant improvement in both groups (Table IV) .
The improvement in both treatment groups was compared by analysis of covariance taking into account the differences in severity of disease on entry to the trial.
The only statistically significant difference between the groups was for the presence of blood in the stool; 5-ASA patients had significantly less blood reported than the bismuth group. The presence of mucus in the stool was not analysed because the bismuth enema itselfhad the appearance of white mucus, which invalidated any comparison.
A comparison of patients who achieved complete symptomatic relief (global clinical grade of 0; defined as less than three motions per day, with formed stools, no urgency, mucus, or blood) showed 18 Among those completing the trial there were no side effects reported. Although 5-ASA enemas were easier to administer (only one patient had difficulty compared with six in the bismuth group), bismuth was easier to retain (eight patients on 5-ASA had difficulties but only two patients on bismuth).
BISMUTH CONCENTRATIONS IN SERUM SAMPLES
Serum samples for measurement of bismuth were collected from 46 patients of whom 25 were in the bismuth group; only those from the bismuth group were analysed at the end of the study. Analysis was by atomic absorption spectrophotometry. 12 After two weeks of treatment median serum bismuth concentration was 3 ng/g (interquartile range 2O0 to 6 0) and at trial exit it was 3 ng/g (interquartile range 1-75 to [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
At two weeks, however, one patient had a serum bismuth concentration well outside this range (44 ng/g); she denied use of any other bismuth medications and the concentration fell to 3 ng/g in the succeeding two weeks. Discussion This is the first controlled trial of a bismuth enema preparation in patients with distal ulcerative colitis. 5-Aminosalicylic acid was used as the alternative treatment because it is one ofthe most effective topical treatments available.'413 After four weeks there were significant improvements in symptoms as well as sigmoidoscopic and histological grades that were of a similar degree in both groups.
Every attempt was made to ensure that the trial was double blind. Although enemas did not appear identical they were only labelled with the trial number. Information about the nature of the enema was withheld from the clinician involved in assessments. The histological assessments were made without knowledge of either patient group or the order of biopsies. The improvements that occurred during treatment with both preparations were similar and did not differ statistically between the groups. The method ofanalysis ofcovariance was used to take into account the small, random differences in severity of disease between treatment groups at the commencement of the trial that arise when random allocation is used Measurements of bismuth in serum samples during the trial enabled us to monitor whether significant accumulation occurred. Median concentrations were low (3 ng/g serum) with narrow ranges. One patient had higher concentrations after two weeks of treatment but not at the conclusion of the trial. There was no evidence of accumulation of bismuth from the enemas. Previous work had suggested accumulation of bismuth in the body when tripotassium Urgency (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) dicitratobismuthate was taken orally, '4 15 although this has been disputed.'6 Our own unpublished data on absorption from these enemas indicates that less than 0-02% of administered bismuth is absorbed. This, and the quoted safe level for serum bismuth (10-50 tg/1)'7 reassures us of the low toxic potential for this enema. The authors of both previous pilot studies of bismuth in colitis were prompted to use the heavy metal because of previous reports of benefit with arsenical compounds.'819 Bismuth has also become popular in recent years as a treatment in peptic ulcer to eradicate Helicobacter pylori. It has been used for many years in traveller's diarrhoea, as a colostomy deodoriser, and as an antispirochetal agent in syphilis.1" 20 The carbomer 934P is a synthetic polyacrylate characterised by multiple side chains of carboxyl groups. In the pharmaceutical industry it is used as a suspending agent for liquids and as a binder in tablets. It has been shown to promote gel formation with mucin monomers from both gastric and colonic mucus.2' In the colon it also inhibits faecal protease activity, which is responsible for mucolysis and solubilisation of the adherent layer of mucus gel. We found that bismuth compounds, both citrate and subsalicylate, formed soluble complexes with the carbomer and at pH 6 4 to 7 5 produced a viscous mucus-like solution that was convenient to administer and retain as an emena. We used carbomer primarily as a vehicle for the bismuth to try to achieve adherence to the surface mucosa with optimal topical application of the bismuth. In ulcerative colitis the adherent visible layer of mucus is absent from actively inflamed areas -a feature that does not apply in Crohns disease. 22 The nature of any factors within the colonic lumen that may be responsible for either the initiation or continuation of inflammation remains unknown but recent attention has focused on the possible role of flora associated with the mucosa.2' Support for this comes from the finding that faecal protease activity, largely derived from bacteria, is increased threefold in colitis.24 Because bismuth is known to have a toxic effect on some microorganisms its therapeutic benefit in colitis may be related to this. 25 Whether loss of the adherent mucus is related to anaerobic flora associated with the mucosa is an interesting possibility. An ulcerative colitis: a controlled trial.
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